Hilbert Zeballos Evangelista, MD
Hospitalist · Apopka, FLNPI 1700807526
Payments from drug & device makers
Across 94 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$219
- AstraZeneca$185
- Seagen Inc.$181
- Incyte Corporation$157
- Bayer$133
- Amarin Pharma, Inc.$96
- plus $1K from 33 others
What the payments were for
- Food & beverage$1,93596%
- Education$914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $219 |
| AstraZeneca(2 entities) | 8 | $185 |
| Seagen Inc. | 6 | $181 |
| Incyte Corporation | 7 | $157 |
| Bayer | 7 | $133 |
| Amarin Pharma, Inc. | 1 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Sanofi | 4 | $75 |
| Sobi, Inc | 3 | $71 |
| Novartis | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $51 |
| Amgen | 3 | $47 |
| Pfizer | 2 | $43 |
| Eisai Inc. | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Pharmaessentia USA Corporation | 1 | $27 |
| Exelixis Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Emmaus Medical, Inc. | 1 | $17 |
| Novocure Inc. | 1 | $17 |
| Fortovia Therapeutics, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| Verastem, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $12 |
| Servier Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,026 in reported general payments places this provider in the 90th percentile of 1,570 hospitalist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $80,460 |
| EliquisApixaban | 160 | $48,729 |
| XareltoRivaroxaban | 136 | $38,601 |
| TrulicityDulaglutide | 44 | $29,853 |
| LinzessLinaclotide | 30 | $17,265 |
| TradjentaLinagliptin | 35 | $10,414 |
| JardianceEmpagliflozin | 22 | $8,598 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 25 | $7,548 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $7,139 |
| Gabapentin | 200 | $6,216 |
| FarxigaDapagliflozin Propanediol | 15 | $5,998 |
| Sevelamer Carbonate | 28 | $5,822 |
| Levetiracetam | 78 | $5,671 |
| GemtesaVibegron | 13 | $5,577 |
| Memantine Hcl | 89 | $5,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $48,729160 claims |
| Johnson & JohnsonXarelto | $51 | $38,601136 claims |
| AstraZenecaFarxiga, Brilinta | $185 | $8,48026 claims |
| GSKArexvy | $23 | $7,54825 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $5,12013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,570 hospitalist providers in Florida.
Other hospitalist in Apopka
- Mayra AbreuApopka$33K
- Diego MunozApopka$17K
- Gerald BahrApopka$4K
- Sandi ColemanMiami$2.6M
- Miguel Mujica BaellaMiami$1.8M
- Fernando PedrazaMiami$1.8M
- Jose PineroMiami$1.1M
- Jose NegrinHomestead$674K
- Fernando Piedra ChavezMiami$554K
- Felipe Gascon-RodonPembroke Pines$441K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.